ClinicalTrials.gg
Active, not recruitingNCT06484543Updated Apr 9, 2026

Brown Fat as Therapeutic Strategy for Obesity and Associated Metabolic Diseases Via Functional Food/Nutraceutical Approach - Molecular Mechanisms of Pentacyclic Triterpenes (BRACE)

An interventional study of Maslinic Acid and Placebo in Diabetes and Brown Adipose Tissue, sponsored by Institute for Human Development and Potential (IHDP), Singapore. Active, not recruiting at 1 site in Singapore. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Institute for Human Development and Potential (IHDP), Singapore · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Diabetes Mellitus with a site in Singapore — 10 open to participants now, 15 under way, none of them phase 3. Diabetes Mellitus · Singapore.

Planned enrollment
50th of 73
50 · median 137
Started
2024
with 2 others
No phase
50 of 89
8 open now
Primary completion
2027-08
later than 9 of 14 live
Registered
83rd of 89
by date

Among the 89 studies in Diabetes Mellitus with a site in Singapore, this one is the 50th largest by planned enrollment of the 73 interventional ones that give a count, is one of 3 that started in 2024, is one of 50 with no phase, reaches primary completion later than 9 of the 14 other live ones, and was the 83rd registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

10 of the 89 studies in Diabetes Mellitus with a site in Singapore are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 21 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Diabetes Mellitus with a site in Singapore, or all of them as a file.
02

Study summary

To examine MA (Maslinic Acid) safety and efficacy in ameliorating insulin resistance and the cardinal features of metabolic syndrome. Chronic exposure to MA as a potent PPARgamma binder nutraceutical over 12 weeks will result in improvement in the features of metabolic syndrome including waist circumference, blood pressure, serum HDL-C level, fasting serum triglycerides and fasting plasma glucose. Expected secondary endpoints include favorable changes in metabolic rate, respiratory quotient, fat oxidation, body composition, weight, BAT/WAT compartments, batokines/adipokines, proinflammatory biomarkers, insulin sensitivity and beta cell function.

Read the detailed description

Up to 50 participants that are overweight/obese people suffering from metabolic syndrome/pre-metabolic syndrome will be recruited for this study. They will be asked to come to the Clinical Nutrition Research Centre (CNRC) for a screening session (1st visit) and given plenty of time to read this information sheet and the opportunity to ask questions. Once they are fully informed regarding the study and all their questions have been satisfactorily answered, they will be given a consent form to complete and sign in the presence of the researcher. Following this, in order to gauge their suitability for taking part in the study, an assessment will be carried out. This assessment needs to be carried out in a fasted state and they would therefore have to come one morning following an overnight fast. The screening will include anthropometric measurements, blood pressure measurement and blood sampling. Anthropometric measurements taken will be height, weight, waist circumference and hip circumference. Body composition will be measured using an electrical impedance analyser (BIA). Blood pressure will be measured using an automatic blood pressure monitor. They will also undergo a blood sampling from their vein (6 mL or approximately 1.5 teaspoons) to be tested for thyroid function, glucose and lipid profile. Once they have been accepted into the study, they will then be expected to come to the centre for a total of four separate test sessions, over a span of approximately 3 months (two test sessions each at week 0 (before intervention) and at week 12 (after intervention) which will be scheduled within 4 weeks from each timepoint) and will be randomly assigned (via www.random.org) to either the MA or placebo groups below (up to 25 subjects per group). This is a single-blind study in which the participants will not know which group will be assigned to and only the investigators will know. After completing the two test sessions for week 0, both groups will start consuming either the 60mg of MA or placebo once (depending on which group they are assigned to) daily after breakfast for 12 weeks. For each of the four test sessions, they will be required to fast overnight and avoid caffeine and alcohol for 8-10 hours before reporting at the CNRC in the morning between 8 to 9 AM. Only plain water can be consumed during the fast. They are to avoid any physical activity/exercise and alcohol on the day prior to the visit. The test sessions will be as follows: On the first test session (2nd visit) at week 0 (before intervention), they will need to come to CNRC in the morning in a fasted state and an intravenous indwelling cannula will be inserted into an arm vein to collect a fasting blood sample (40ml or approximately 8 teaspoons) and an urine sample will also collected. They will then proceed to undergo metabolic rate measurement with IRT focusing on their neck and area above the collar bone in a whole body room calorimeter (WBC) for the next 45 minutes. They will then undergo a mild cold stimulation of about 14 degree Celcius by wearing a cooling vest for the next 1.5 hours, in which metabolic rate measurement and IRT in the WBC will be performed during this period. Wearing the cooling vest may lead to some shivering, but it is generally considered safe. Upon exiting the WBC, they will remove the cooling vest and 20ml (approximately 4 teaspoons) of blood sample and another urine sample will be collected again. After which, they will be free to leave.On the second test session (3rd visit) at week 0 (before intervention), they will need to come to CNRC in the morning in a fasted state and anthropometric measurements like height, weight, waist circumference and hip circumference will be taken. Body composition will be measured using an electrical impedance analyser (BIA) and blood pressure will be measured using an automatic blood pressure monitor. They will then undergo a body composition evaluation using dual energy X-ray absorptiometry (DXA) (approximately 20 mins duration) which allows quantification of fat, lean and bone mass. After that, an intravenous indwelling cannula will be inserted into an arm vein to collect a fasting (timepoint 0min) blood sample (5ml or approximately 1 teaspoon). Subsequently they will undergo a 120-minutes oral glucose tolerance test (OGTT) where you will be required to consume a glucose drink (75g of glucose) within 5 minutes. Following the consumption of the glucose drink, we will take further blood samples (from the cannula) every 30 minutes for the remaining 120 minutes (4 timepoints at 30, 60, 90 and 120 min). At each time point, approximately 5 ml or approximately 1 teaspoon of blood will be drawn.

During the entire test session, they will have to stay rested and in the laboratory. Television and a workspace will be provided for their use if they require. At the end of 2 hours of testing, they will be free to leave. The above 2 test sessions may be scheduled in any order, but to be completed no more than 4 weeks apart. They will now start the study intervention for the next 12 weeks. Depending on which group they are assigned to, they will be instructed to consume either 60mg of MA or placebo daily (after breakfast) for the next 12 weeks. They will then be required to come for the third test session (4th visit) and fourth test session (5th visit) at week 12 (after completing the 12 weeks of intervention), and repeat the same procedures as per that of the first test session (2nd visit) and the second test session (3rd visit) respectively. The 2 test sessions each at week 0 and 12 may be scheduled within 4 weeks from each time point. During the course of the study, there is a possibility that we might unintentionally come to know of new information about their health condition from (e.g. the screening blood test, etc.) that are conducted as part of the study. These are called "incidental findings". "Incidental findings" are findings that have potential health or reproductive importance to research participants like you and are discovered in the course of conducting the study, but are unrelated to the purposes, objectives or variables of the study. These findings may affect your current or future life and/or health insurance coverage. Examples of potential incidental findings that may be discovered during the course of this study may include but are not limited to greater than normal range of fasting glucose, insulin, C-peptide or HbA1C (possibly indicating type 2 diabetes), abnormal lipid profile (e.g., high triglycerides) or thyroid hormones (e.g. TSH, FT4). Incidental finding (IF) management workflow:- Participants will be asked during informed consent if they would like to be re-identified and re-contacted in the event of an incidental finding (IF) during the course of future research. Study participant wishes on the return of IF are documented in the informed consent form utilized by the study team. - A list of coded study IDs who have indicated their wish on the return of IF will be provided to the PI.- The PI will evaluate the findings with a competent and qualified clinician/healthcare professional/ study doctor. The PI will confirm against the consent form that the participant had indicated their wishes to be re-identified and re-contacted in the event of an IF. If so, the study participant will be de-identified by the PI to contact the participant.- The PI (or his/her study team) will re-contact the participant and re-confirm if participant would like to be informed of the IF. The IF and its relevant information will be provided to the participant according to their preferred manner (either electronically or physical copy). They will be advised to seek a medical practitioner for further evaluation to reconfirm the IF. In the event that the participant is non-contactable, the study team will need to demonstrate and document that reasonable efforts have been made to re-contact the participant or next of kin. The PI (or his/her study team) will document the above in the study records. The PI (or his/her study team) will also update study folder that the loop has been closed.

03

Conditions studied

  • Diabetes
  • Brown Adipose Tissue

Browse trials for

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female
  • Chinese ethnicity
  • Age between 21 to 60 years• Able to give
  • (BMI) between 23 to 32 kg/m2
  • Thyroid function test must be within the normal ranges
  • Willing to avail yourself for the whole study and follow study procedures
  • EITHER deemed to have pre-metabolic syndrome when waist circumference is > 90 cm in men or > 80 cm in women, with none or up to one of the following condition:

    1. Triglyceride level >/= 1.7 mmol/L
    2. HDL cholesterol \</= 1.0 mmol/L in men, and \</= 1.3 mmol/L in women
    3. Blood pressure >/= 130/85 mmHg
    4. Fasting blood glucose >/= 6.1 mmol/L
  • OR deemed to have metabolic syndrome when three or more of the following conditions are present:

    1. Waist circumference > 90 cm in men and > 80 cm in women
    2. Triglyceride level >/= 1.7 mmol/L
    3. HDL cholesterol\</= 1.0 mmol/L in men, and \</= 1.3 mmol/L in women
    4. Blood pressure >/= 130/85 mmHg
    5. Fasting blood glucose >/= 6.1 mmol/L

Exclusion criteria

Exclusion Criteria:

  • Are pregnant or contemplating pregnancy (for female subjects)
  • Partake in sports at the competitive and/ or endurance levels
  • Have known glucose-6-phosphate dehydrogenase (G6PD) deficiency
  • Have major chronic disease such as heart disease or cancer
  • Take insulin or drugs known to affect glucose metabolism
  • Intentionally restrict food intake
  • Have major medical or surgical event requiring hospitalization within the preceding 3 months
  • Have taken antibiotics for 3 months before the study period
  • Are a smoker
  • Are an overnight shift worker
  • Have any known food allergy (eg. anaphylaxis to peanuts) or skin allergy (eg. rashes due to alcohol, etc)
  • Having active Tuberculosis (TB) or currently receiving treatment for TB
  • Have any known Chronic Infection or known to suffer from or have previously suffered from or is a carrier of Virus (HBV), Virus (HCV), (HIV)
  • Are a member of the research team or their immediate family members. Immediate family member is defined as a spouse, parent, child, or sibling, whether biological or legally adopted
  • Enrolled in a concurrent research study judged not to be scientifically or medically compatible with this study
  • Have poor veins impeding venous access
  • Have any history of severe vasovagal syncope (blackouts or near faints) following blood draws
  • History of claustrophobia
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Maslinic Acid

    MA (an extract from olive fruit). Each participant will be instructed to take 3 tablets (60 mg or equivalent) daily after breakfast for 12 weeks.

    Other: Maslinic Acid

  • Placebo comparator
    Placebo

    Each subject will be instructed to take 3 matching placebo tablets (or equivalent) daily after breakfast for 12 weeks.

    Other: Placebo

Interventions

  • OtherMaslinic Acid

    Consumption of Maslinic Acid for 12 weeks

  • OtherPlacebo

    Consumption of Placebo for 12 weeks

06

What researchers measure

Primary outcomes

  1. Concentration of blood glucose

    Time frame: Week 0, 12

  2. Rate of brown adipose tissue activation detection using Infrared camera

    Time frame: Week 0, 12

  3. Change in Energy Expenditure using Whole Body Calorimeter

    Time frame: Week 0, 12

  4. Change in Body Mass Index (BMI)

    Measurement of weight and height

    Time frame: Week 0, 12

  5. Change in Fat percentage

    Time frame: Week 0, 12

  6. Concentration of Insulin level

    Time frame: Week 0, 12

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Aug 2027, 36 months after the start.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 36 months is above that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2024
First posted
Jul 3, 2024
StartActual
Aug 15, 2024
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06484543
Lead sponsor
Institute for Human Development and Potential (IHDP), Singapore
Collaborators
National Medical Research Council (NMRC), Singapore
Responsible party
Melvin Leow (Principal Investigator, Institute for Human Development and Potential (IHDP), Singapore) — Principal investigator
First posted
Jul 3, 2024
Start date
Aug 15, 2024
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Apr 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion